214 results on '"Michael Fraser"'
Search Results
2. Operational Performance of a Compact Proton Therapy System: A 5-Year Experience
3. The telomere length landscape of prostate cancer
4. Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse
5. CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer
6. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer
7. Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation.
8. Valection: design optimization for validation and verification studies
9. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations
10. Mitochondrial mutations drive prostate cancer aggression
11. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories
12. Use of Sequenom sample ID Plus® SNP genotyping in identification of FFPE tumor samples.
13. Student Perceptions of Teacher-Generated Educational Videos Shown in a Korean EFL Classroom
14. Design criteria for rolling contact fatigue resistance in back-up rolls
15. Comparison of pre-processing methods for Infinium HumanMethylation450 BeadChip array.
16. Student Perceptions of Teacher-Generated Educational Videos Shown in a Korean EFL Classroom
17. Supplementary Data 2 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
18. Supplementary Table 5 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
19. Supplementary Table 2 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
20. Supplementary Table 6 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
21. Supplementary Table 1 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
22. Supplementary Data 3 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
23. Supplementary Table 7 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
24. Data from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
25. Supplementary Figure 2 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
26. Supplementary Data from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
27. Supplementary Figure 4 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
28. Supplementary Figure 1 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
29. Supplementary Figure 4 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
30. Supplementary Figure 6 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
31. Supplementary Table 4 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
32. Supplementary Figure Legends 1-5 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
33. Supplementary Figure 1 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
34. CCR Translation for This Article from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
35. Supplementary Figure 2 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
36. Supplementary Table 3 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
37. Supplementary Figure 5 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
38. Supplementary Table 8 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
39. Supplementary Figure 3 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
40. Supplementary Data 1 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
41. Data from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
42. Supplementary Figure 5 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
43. Supplementary Data 4 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
44. Supplementary Table 1 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
45. Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
46. Challenges in managing miners
47. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
48. Revealing Solid Electrolyte Interphase Formation Through Interface-Sensitive Operando X-ray Absorption Spectroscopy
49. Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management
50. Priapism toolbox: facilitating emergency management of ischaemic priapism and improving safety of intracavernosal phenylephrine use
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.